Serum Institute If India
- All
- News
- Videos
-
What If Adar Poonawalla Doesn't Want It: High Court Scraps Plea On Security
The Maharashtra government has told the Bombay High Court that it would provide security to Adar Poonawalla, CEO of the Serum Institute of India (SII) which manufacturers the Covishield vaccine against COVID-19, if he makes a request.
-
"Vaccine More Effective If Longer Gap Between Doses": Serum To NDTV
The efficacy of the Covishield vaccine goes up if the gap between two doses is more than 28 days, a top scientist at Adar Poonawalla's Serum Institute of India (SII) said today, a day before the launch of India's Covid vaccination drive.
-
Serum Institute's Fact Sheet For Recipients Of Covishield Vaccine
Ahead of the COVID-19 vaccination drive that starts Saturday, Serum Institute of India, whose Covishield vaccine will be administered in the nationwide drive, has uploaded a fact sheet on its website to dispel doubts about its vaccine. The document addresses a wide range of frequently asked questions, including the risk and benefits of its vaccine ...
-
Oxford Vaccine At Rs. 1,000 If Centre Allows Us To Sell: Adar Poonawalla
The Serum Institute of India's Covishield vaccine, which has got approval from the country's drug regulator, will be commercially available at Rs 1,000 per dose if the government allows sale in retail, company chief Adar Poonawalla has said.
-
India's Wait Over, Drug Regulator Says Covid Vaccines Cleared "110% Safe"
Two vaccines for coronavirus, Oxford University's Covishield, which is being developed by the Pune-based Serum Institute, and Bharat Biotech's Covaxin, received emergency approval from the country's drug regulator on Sunday. "We'll never approve anything if there is slightest of safety concern. The vaccines are 110 per cent safe," Drug Controller G...
-
After Pfizer, Serum Institute Of India Seeks Approval For Covid Vaccine
Serum Institute of India, the world's largest vaccine maker by number of doses produced, has sought government approval for emergency use authorisation of the coronavirus vaccine that it is developing with the University of Oxford and British drugmaker AstraZeneca, sources have said.
-
"Covid Vaccine Will Be Found In...": NCP's Supriya Sule's Dig At PM Modi
Even if one goes around the world, vaccine for COVID-19 will be found only in Pune, NCP MP Supriya Sule said on Saturday, referring to Prime Minister Narendra Modi's visit to the Serum Institute of India (SII).
-
"100 Million Doses By January," Says Adar Poonawalla On Oxford Vaccine
A minimum of 100 million doses of Covishield - a coronavirus vaccine that on Monday morning was said to be 90 per cent effective under certain conditions - will be available by January and hundreds of million could be ready by the end of February, Adar Poonawalla of the Serum Institute of India told NDTV.
-
E&Y honours Ratan Tata with life-time achievement award
Leading accounting and consultancy firm ernst & Young (E&Y) India has awarded the Tata Group patriarch Ratan Tata, the chairman Emeritus of the $100-billion conglomerate, with the entrepreneur of the year lifetime achievement award.
-
What If Adar Poonawalla Doesn't Want It: High Court Scraps Plea On Security
The Maharashtra government has told the Bombay High Court that it would provide security to Adar Poonawalla, CEO of the Serum Institute of India (SII) which manufacturers the Covishield vaccine against COVID-19, if he makes a request.
-
"Vaccine More Effective If Longer Gap Between Doses": Serum To NDTV
The efficacy of the Covishield vaccine goes up if the gap between two doses is more than 28 days, a top scientist at Adar Poonawalla's Serum Institute of India (SII) said today, a day before the launch of India's Covid vaccination drive.
-
Serum Institute's Fact Sheet For Recipients Of Covishield Vaccine
Ahead of the COVID-19 vaccination drive that starts Saturday, Serum Institute of India, whose Covishield vaccine will be administered in the nationwide drive, has uploaded a fact sheet on its website to dispel doubts about its vaccine. The document addresses a wide range of frequently asked questions, including the risk and benefits of its vaccine ...
-
Oxford Vaccine At Rs. 1,000 If Centre Allows Us To Sell: Adar Poonawalla
The Serum Institute of India's Covishield vaccine, which has got approval from the country's drug regulator, will be commercially available at Rs 1,000 per dose if the government allows sale in retail, company chief Adar Poonawalla has said.
-
India's Wait Over, Drug Regulator Says Covid Vaccines Cleared "110% Safe"
Two vaccines for coronavirus, Oxford University's Covishield, which is being developed by the Pune-based Serum Institute, and Bharat Biotech's Covaxin, received emergency approval from the country's drug regulator on Sunday. "We'll never approve anything if there is slightest of safety concern. The vaccines are 110 per cent safe," Drug Controller G...
-
After Pfizer, Serum Institute Of India Seeks Approval For Covid Vaccine
Serum Institute of India, the world's largest vaccine maker by number of doses produced, has sought government approval for emergency use authorisation of the coronavirus vaccine that it is developing with the University of Oxford and British drugmaker AstraZeneca, sources have said.
-
"Covid Vaccine Will Be Found In...": NCP's Supriya Sule's Dig At PM Modi
Even if one goes around the world, vaccine for COVID-19 will be found only in Pune, NCP MP Supriya Sule said on Saturday, referring to Prime Minister Narendra Modi's visit to the Serum Institute of India (SII).
-
"100 Million Doses By January," Says Adar Poonawalla On Oxford Vaccine
A minimum of 100 million doses of Covishield - a coronavirus vaccine that on Monday morning was said to be 90 per cent effective under certain conditions - will be available by January and hundreds of million could be ready by the end of February, Adar Poonawalla of the Serum Institute of India told NDTV.
-
E&Y honours Ratan Tata with life-time achievement award
Leading accounting and consultancy firm ernst & Young (E&Y) India has awarded the Tata Group patriarch Ratan Tata, the chairman Emeritus of the $100-billion conglomerate, with the entrepreneur of the year lifetime achievement award.
